Menopause tends to nudge weight up, and a lot of women now reach for a GLP-1 medication to deal with it. Early observational data suggest that women who also take hormone therapy may lose a bit more on one of those drugs. It’s an interesting signal. It isn’t proof, and it comes from a very small study. Here’s what the research actually supports, and what to ask your clinician.
The study behind the idea
A 2024 Mayo Clinic study looked at postmenopausal women treated with semaglutide. It was a retrospective cohort of women treated for at least three months: 16 women on hormone therapy and 90 who were not. At 12 months, the hormone therapy group had lost about 16% of body weight compared with about 12% in the other group, and the difference held after the authors adjusted for confounders. Both groups improved on glucose, blood pressure, and lipid markers. The authors themselves said larger studies were needed to confirm it.[1]
Sixteen women on hormone therapy is a very small group, and the study was observational, so treat it as a hypothesis, not a result.
Why observational data can mislead here
In a records-based study, nobody was randomly assigned to hormone therapy. Women who use it differ from those who don’t in ways that also affect weight loss: how early they started care, how closely they’re followed, how motivated they are, their health history, even who feels able to access it. Statistical adjustment helps, but it can’t remove every difference. That’s why a study like this cannot show that hormone therapy caused the extra loss, and why it is not a reason to start hormone therapy for weight loss.
There’s also the scale of the effect. A gap of about four percentage points of body weight, in a group this small, is interesting in a spreadsheet but modest in a life. It also says nothing about what kind of weight was lost, since weight on a scale mixes fat and lean mass. If you’re on any GLP-1, protecting muscle matters more than a pound or two. I covered that in GLP-1 and Muscle: What Protein and Strength Guidance Says.
A more solid link: estrogen and insulin sensitivity
There is randomized-trial evidence for one plausible piece of the story. A 2025 meta-analysis pooled 17 randomized trials with 5,772 non-diabetic postmenopausal women, with treatment lasting from 8 weeks to 3 years. Hormone therapy lowered HOMA-IR, a calculated marker of insulin resistance, compared with placebo. Estrogen alone showed a larger reduction than estrogen plus a progestogen. That is a marker of how the body handles insulin, not a measure of weight loss, and the trials were heterogeneous. Still, it fits the idea that estrogen status interacts with metabolism in ways that could matter for how you respond to these medications.[2]
What this means if you’re in midlife
- Hormone therapy is a decision about symptoms and long-term health risks and benefits, made with a clinician who knows your history. Weight is, at best, a side note. My overview of the broader picture is in HRT and TRT: Separating Evidence from Marketing.
- If you’re already taking a GLP-1, don’t add or drop hormone therapy based on this. The data doesn’t support that.
- The basics still carry the weight: enough protein, resistance training two to three times a week, sleep, and a plan for what happens if you stop the medication, since weight regain is common after stopping.
- If your symptoms started in your 40s, perimenopause can drive weight and body composition changes well before periods stop. It’s worth raising early.
Questions for your next appointment
- Given my history, am I a candidate for hormone therapy for my symptoms, separate from weight?
- If I’m taking or considering a GLP-1, which one fits me, and how will we track muscle and strength, not just the scale?
- Is there a clinical trial of combined therapy I could ask about?
- What’s my plan if I stop the GLP-1?
The evidence here is early and observational, and it comes from a small group of postmenopausal women, so it may not apply to you.
References
[1] Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4):266-274. DOI: 10.1097/GME.0000000000002310. Finding as used: retrospective cohort, 16 women on hormone therapy versus 90 not; total body weight loss at 12 months 16 ± 6% versus 12 ± 8% (P = 0.04), association remained after adjustment; cardiometabolic markers improved in both groups; authors call for larger studies. ↑︎
[2] Li T, Jiang NS, Kaskey J, et al. Hormone therapy and insulin resistance in non-diabetic postmenopausal women: a systematic review and meta-analysis. Climacteric. 2025;28(6):673-681. DOI: 10.1080/13697137.2025.2509844. Finding as used: 17 randomized trials, 5,772 women; hormone therapy lowered HOMA-IR versus placebo (raw mean difference -0.24, 95% CI -0.32 to -0.16); estrogen alone -0.42, estrogen plus progestogen -0.14. ↑︎
Kurt Greiner
Kurt is a digital strategist and IT professional blending emerging technology with practical application, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.
Leave a Reply